| Autor: |
Chen, Sizhu Amelia, Arutyunova, Elena, Lu, Jimmy, Khan, Muhammad Bashir, Rut, Wioletta, Zmudzinski, Mikolaj, Shahbaz, Shima, Iyyathurai, Jegan, Moussa, Eman W., Turner, Zoe, Bai, Bing, Lamer, Tess, Nieman, James A., Vederas, John C., Julien, Olivier, Drag, Marcin, Elahi, Shokrollah, Young, Howard S., Lemieux, M. Joanne |
| Zdroj: |
ACS Central Science; April 2023, Vol. 9 Issue: 4 p696-708, 13p |
| Abstrakt: |
The main protease of SARS-CoV-2 (Mpro) is the most promising drug target against coronaviruses due to its essential role in virus replication. With newly emerging variants there is a concern that mutations in Mpromay alter the structural and functional properties of protease and subsequently the potency of existing and potential antivirals. We explored the effect of 31 mutations belonging to 5 variants of concern (VOCs) on catalytic parameters and substrate specificity, which revealed changes in substrate binding and the rate of cleavage of a viral peptide. Crystal structures of 11 Mpromutants provided structural insight into their altered functionality. Additionally, we show Mpromutations influence proteolysis of an immunomodulatory host protein Galectin-8 (Gal-8) and a subsequent significant decrease in cytokine secretion, providing evidence for alterations in the escape of host-antiviral mechanisms. Accordingly, mutations associated with the Gamma VOC and highly virulent Delta VOC resulted in a significant increase in Gal-8 cleavage. Importantly, IC50s of nirmatrelvir (Pfizer) and our irreversible inhibitor AVI-8053 demonstrated no changes in potency for both drugs for all mutants, suggesting Mprowill remain a high-priority antiviral drug candidate as SARS-CoV-2 evolves. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
